Pharmaceutical indicated for the treatment of mast cell tumours in dogs
Tigilanol tiglate is approved for treating mast cell tumours (MCT) in dogs, removing 75% of tumours with a single treatment (p=0.0001).1
It is a first-in-class, small, cell signalling molecule approved by the European Medicines Agency (EMA), the UK Veterinary Medicines Directorate (VMD) and Swissmedic as an oncology pharmaceutical for the treatment of all grades of non-metastatic, non-resectable MCT in dogs.2 It has also been approved by the Food and Drug Administration (FDA), Australian Pesticides and Veterinary Medicines Authority (APVMA) and is marketed across these geographies.
Proactive lifecycle management
Our Phase IV programme is currently underway to explore the potential of additional solid tumour indications.
OUR STORY
2000
2000
2000
2002-2004
2004
2004
2005
2005
2006
2007
2008
>200 cases (89 MCT)
2009-2013
2010
2010-2014
in all major markets
2010-2014
and pharmacokinetics PK (27 MCT)
2013
2014
2015
2015
(123 MCT)
2015
2017
with Virbac for tigilanol tiglate veterinary in EU, UK and USA
2018
of tigilanol tiglate as a canine MCT treatment
2019
2019
2019
of tigilanol tiglate as a canine MCT treatment
2019
2020
2020
2020
2020
2020
2021
References:
- De Ridder TR et al. Journal of Veterinary Internal Medicine 2020;doi:10.1111/jvim.15806
- Tigilanol tiglate Summary of Product Characteristics v 5018-en.
